[1] [1] LIU C A, CHANG C Y, HSUEH K W, et al. Migration/invasion of malignant gliomas and implications for therapeutic treatment［J］. International Journal of Molecular Sciences, 2018, 19(4): 11-15.

[2] [2] COHEN A L, COLMAN H. Glioma biology and molecular markers［J］. Cancer Treat and Research, 2015, 163(6): 15-30.

[3] [3] LOUIS D N, PERRY A, REIFENBERGER G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary［J］. Acta Neuropathologica, 2016, 131(6): 803-820.

[4] [4] SIEBZEHNRUBL F A, REYNOLDS B A, VESCOVI A, et al. The origins of glioma: E pluribus unum?［J］. Glia, 2011, 59(8): 1135-1147.

[5] [5] TOMIYAMA A, ICHIMURA K. Signal transduction pathways and resistance to targeted therapies in glioma［J］. Seminars in Cancer Biology, 2019, 58(10): 256-263.

[6] [6] BARR R K, BOGOYEVITCH M A. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs)［J］. The International Journal of Biochemistry & Cell Biology, 2001, 33(11): 1047-1063.

[7] [7] DAVIS R J. Signal transduction by the JNK group of MAP kinases［J］. Cell, 2000, 2(103): 239-252.

[8] [8] MARIE A, BOGOYEVITCH. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases［J］. Microbiology and Molecular Biology Reviews: 2006, 4(70): 1061-1095.

[9] [9] LAN K P. Induced eosinophilia and proliferation in angiostrongylus cantonensis-infected mouse brain are associated with the induction of JAK/STAT1, IAP/NF-kappaB and MEKK1/JNK signals［J］. Journal of Helminthology, 2004, 4(78): 311-317.

[10] [10] BUBICI C, PAPA S. JNK signalling in cancer: in need of new, smarter therapeutic targets［J］. British Journal of Pharmacology, 2014, 171(1): 24-37.

[11] [11] SEKI E, BRENNER D A, KARIN M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches［J］. Gastroenterology, 2012, 143(2): 307-320.

[12] [12] CRISTINA C, CELLURALE W. Role of JNK in a Trp53-dependent mouse model of breast cancer［J］. PLos One, 2010, 8(5): 412-419.

[13] [13] YANG H, CHOI H J, PARK S H, et al. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells［J］. Biochemical Pharmacology, 2009, 78(9): 1205-1213.

[14] [14] GOLD P E. Protein synthesis inhibition and memory: formation vs amnesia［J］. Neurobiology of Learning and Memory, 2008, 89(3): 201-211.

[15] [15] ARUGA N, KIJIMA H, MASUDA R, et al. Epithelial-mesenchymal transition (EMT) is correlated with patient’s prognosis of lung squamous cell carcinoma［J］. The Tokai Journal of Experimental and Clinical Medicine, 2018, 43(1): 5-13.

[16] [16] OSTROM Q T, BAUCHET L, DAVIES F G, et al. The epidemiology of glioma in adults: a “state of the science” review［J］. Neuro Oncology, 2014, 16(7): 896-913.

[17] [17] LIN L, CAI J, JIANG C. Recent advances in targeted therapy for glioma［J］. Current Medicinal Chemistry, 2017, 24(13): 1365-1381.

[18] [18] LUNGHI P, TABILIO A, PINELLI S, et al. Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts［J］. The Hematology Journal: The Official Journal of the European Haematology Association, 2001, 2(2): 70-80.

[19] [19] MATSUDA K I, SATO A, OKADA M, et al. Targeting JNK for therapeutic depletion of stem-like glioblastoma cells［J］. Scientific Reports, 2012, 2(516): 1-11.

[20] [20] RANA A, RANA B, MISHRA R, et al. Mixed lineage kinase-c-Jun N-terminal kinase axis: a potential therapeutic target in cancer［J］. Genes Cancer, 2013, 4(9/10): 334-341.

[21] [21] LIU X, ZHAO P, WANG X, et al. Triptolide induces glioma cell autophagy and apoptosis via upregulating the ROS/JNK and downregulating the Akt/mTOR signaling pathways［J］. Frontiers in Oncology, 2019, 9(9): 1-16.

[22] [22] LIU X, ZHAO P, WANG X, et al. Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells［J］. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 1-18.